Syncom Formulation (India) (BOM:524470) Moat Score: 0/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524470 Syncom Formulation (India) Ltd BOM:524470
86 GF Score
Price ₹12.94
GF Value ₹20.13
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Syncom Formulation (India) Moat Score?

Syncom Formulation (India) has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Syncom Formulation (India) has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Syncom Formulation (India) might have No Moat - No discernible moat.

Syncom Formulation (India)  (BOM:524470) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Syncom Formulation (India) Moat Score Related Terms

BOM:524470
86GF Score
Syncom Formulation (India) Ltd BOM:524470
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹12.94 is trading 35.7% below its estimated GF Value™ of ₹20.13. GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.

Key valuation signals for BOM:524470:

  • Moat Score: 0
  • GF Value™: ₹20.13 vs. price of ₹12.94 (35.7% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syncom Formulation (India) Business Description

Other Exchanges SYNCOMF:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score

Get the complete analysis for BOM:524470

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹12.94
Price
₹20.13
GF Value